Fibrinogen concentrate - Octapharma

Drug Profile

Fibrinogen concentrate - Octapharma

Alternative Names: Factor I concentrate; Octafibrin

Latest Information Update: 19 May 2016

Price : $50

At a glance

  • Originator Octapharma
  • Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
  • Mechanism of Action Fibrinogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Afibrinogenaemia

Most Recent Events

  • 01 Dec 2015 Phase-III clinical trials in Afibrinogenaemia (In children, In infants) in Lebanon, Iran, India (IV) (NCT02408484)
  • 09 Apr 2015 Octapharma plans a phase III trial for Afibrinogenaemia (In infants, In children) in USA and India (NCT02408484)
  • 01 Sep 2014 Phase-III clinical trials in Afibrinogenaemia in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top